2 Seventy Bio Inc (TSVT)

Apr 04, 2025

Layoff Tracker: Relay Will Cut 70 Employees, Affecting Research Budget by 75% - BioSpace

Apr 04, 2025

Mar 30, 2025

Charles Schwab Investment Management Inc. Has $1.26 Million Position in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World

Mar 30, 2025

Mar 13, 2025

Bristol Meyers Squibb to Acquire 2seventy bio - Contract Pharma

Mar 13, 2025

Mar 13, 2025

2seventy bio, Inc. (NASDAQ:TSVT) Receives $7.20 Consensus PT from Analysts - Defense World

Mar 13, 2025

Mar 11, 2025

In buying cell therapy partner 2seventy bio for $286M, BMS takes full control of Abecma - Fierce Pharma

Mar 11, 2025

Mar 10, 2025

2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb - Business Wire

Mar 10, 2025

Mar 10, 2025

Rhumbline Advisers Has $249,000 Holdings in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World

Mar 10, 2025

Mar 06, 2025

2Seventy Bio at TD Cowen Conference: Strategic Growth and Challenges - Investing.com

Mar 06, 2025

Feb 16, 2025

Analysts Set 2seventy bio, Inc. (NASDAQ:TSVT) Target Price at $7.20 - Defense World

Feb 16, 2025

Feb 06, 2025

2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results - Business Wire

Feb 06, 2025

Feb 05, 2025

Gossamer Study Finds Seralutinib Has Long-Lasting Effects in PAH - Managed Healthcare Executive

Feb 05, 2025

Jan 20, 2025

Weiss Ratings Reaffirms “Sell (E+)” Rating for 2seventy bio (NASDAQ:TSVT) - Defense World

Jan 20, 2025

Jan 04, 2025

Barclays PLC Sells 132,019 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World

Jan 04, 2025

Dec 18, 2024

Fmr LLC Has $701,000 Stock Holdings in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World

Dec 18, 2024